Palexia - Key Visual

YOUR SEVERE CHRONIC LOW BACK PAIN PATIENTS WANT:
TO BE ABLE TO STAY ON TREATMENT

Palexia® PR offers...

  • 77% more patients stay on therapy compared to oxycodone/ naloxone4
  • Significantly improved quality of life compared to oxycodone/ naloxone4

Confirmed by patients4

Palexia - Key
Palexia - Key Visual - Stay on therapy

Comparison of
treatment adherencea4

Palexia® - Treatment adherence - Graph
Zoom

PALEXIA® PR - MORE PATIENTS STAY ON THERAPY COMPARED TO OXYCODONE/NALOXONE4


Palexia - Key Visual - Treatment discontinuations

Treatment
discontinuationsb4

Palexia® - Treatment discontinuations - Graph
Zoom

PALEXIA® PR - More patients stay on therapy compared to oxycodone/naloxone4


Palexia - Key Visual - Quality of life

Quality of
Lifed6

Palexia® - Quality of life - Graph
Zoom

PALEXIA® PR - SIGNIFICANTLY IMPROVED QUALITY OF LIFE COMPARED TO OXYCODONE/NALOXONE4


View footnotes

a Studied in low back pain with a neuropathic pain component. Palexia® PR showed less treatment discontinuations for the whole treatment period, compared to oxycodone/naloxone PR, over 12 weeks of treatment; 77% more patients stay on Palexia® PR compared to oxycodone/naloxone PR.

b Studied in low back pain with a neuropathic pain component. Palexia® PR showed less treatment discontinuations for the whole treatment period, compared to oxycodone/naloxone PR, over 12 weeks of treatment.

c includes patients who switched to the pickup arm due to TEAEs or lack of efficacy. Additional reasons for study discontinuation included withdrawal by the patient (tapentadol PR, 3.8% [5/130]; oxycodone/naloxone PR, 7.0% [9/128]); technical problems (tapentadol PR, 0.8% [1/130]; oxycodone/naloxone PR, 0%); protocol deviations (tapentadol PR, 1.5% [2/130]; oxycodone/naloxone PR, 0.8% [1/128]; and other reasons (tapentadol PR, 0.8% [1/130]; oxycodone/naloxone PR, 0%). Palexia® PR refers to tapentadol prolonged-release.

d Studied in low back pain with a neuropathic pain component. Changes from baseline to final evaluation in SF-12 domain and summary scores. Quality of life as indicated by SF-12. All P vales are descriptive.

e Studied in low back pain with a neuropathic pain component. Quality of Life as indicated by patient global impression of change (PGIC); p=0.0031 for the statistical difference (Fischer’s exact test) between tapentadol PR and oxycodone/naloxone PR for % patients reporting very much/much improved at final evaluation; p=0.005 for the statistical difference (Fischer’s exact test) for the overall distribution of responses on the PGIC, was more favourable for tapentadol PR vs oxycodone/naloxone PR.

ABBREVIATIONS
BL, baseline
LOCF, last observation carried foward
LS, least-squares
NPSI, neuropathic pain symptom inventory
PGIC, patient global impression of change
PR, prolonged-release
SF-12, short form-12
TEAE, treatment emergent adverse events